Results 11 to 20 of about 427,029 (392)

The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]

Blood, 2017
Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core   +2 more sources

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Leukemia, 2023
From the laboratory perspective, effective management of patients with chronic myeloid leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential assessment of levels of residual disease and investigation of possible reasons
Nicholas C. P. Cross, Thomas Ernst, S. Branford, J. Cayuela, Michael W. Deininger, A. Fabarius, D. Kim, Katerina Machova Polakova, J. Radich, R. Hehlmann, A. Hochhaus, J. Apperley, S. Soverini   +12 more
semanticscholar   +1 more source

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Leukemia, 2021
In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death ...
H. Kantarjian, T. Hughes, R. Larson, Dong-Wook Kim, S. Issaragrisil, P. le Coutre, G. Étienne, C. Boquimpani, R. Pasquini, R. Clark, V. Dubruille, I. Flinn, S. Kyrcz‐Krzemień, E. Mędraś, M. Zanichelli, I. Bendit, S. Cacciatore, Ksenia Titorenko, P. Aimone, G. Saglio, A. Hochhaus   +20 more
semanticscholar   +1 more source

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Leukemia, 2022
This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five years’ follow-up.
T. Brümmendorf, Jordi Cortés, D. Milojkovic, C. Gambacorti-Passerini, R. Clark, P. le Coutre, V. García‐Gutiérrez, C. Chuah, V. Kota, J. Lipton, P. Rousselot, M. Mauro, A. Hochhaus, R. Hurtado Monroy, E. Leip, S. Purcell, A. Yver, A. Viqueira, M. Deininger   +18 more
semanticscholar   +1 more source

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Leukemia, 2020
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy.
A. Hochhaus, M. Baccarani, R. Silver, C. Schiffer, J. Apperley, F. Cervantes, R. Clark, J. Cortes, M. Deininger, F. Guilhot, H. Hjorth-Hansen, T. Hughes, J. Janssen, H. Kantarjian, Dong-Kee Kim, R. Larson, J. Lipton, F. Mahon, J. Mayer, F. Nicolini, D. Niederwieser, F. Pane, J. Radich, D. Réa, J. Richter, G. Rosti, P. Rousselot, G. Saglio, Susanne Saussele, S. Soverini, J. Steegmann, A. Turkina, A. Zaritskey, Ruediger Hehlmann   +33 more
semanticscholar   +1 more source

Chronic myeloid leukemia [PDF]

Rare Diseases, 2020
This chapter describes the diagnostic criteria, work-up, differential diagnoses, treatment, and treatment response monitoring of chronic myeloid leukemia.
Letícia Antunes Muniz Ferreira
semanticscholar   +5 more sources

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

Leukemia, 2021
The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors (TKIs).
Y. Hsieh, K. Kirschner, M. Copland
semanticscholar   +1 more source

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase [PDF]

Vojnosanitetski Pregled, 2022
Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase of chronic myeloid leukemia.
Sekulić Borivoj, Perčić Ivanka, Dragičević-Jojkić Marina, Dokić Marina, Panjković Milana   +4 more
doaj   +1 more source

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]

, 2014
Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI, Greco M, LA NASA, GIORGIO   +2 more
core   +2 more sources

Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future

Cells, 2021
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning with the first discovery of leukemia and the description of the Philadelphia Chromosome and ending with the current goal of achieving treatment-free remission after ...
Valentina R Minciacchi, Rahul Kumar, D. Krause   +2 more
semanticscholar   +1 more source